Peer reviewed original articles

1. Brockow I., Nennstiel U. Parents' experience with positive newborn screening results for cystic fibrosis 2019
   European Journal of Pediatrics https://doi.org/10.1007/s00431-019-03343-6

2. Brockow I., Nennstiel U. Neugeborenen-Screening auf Mukoviszidose
   Gynäkologische praxis 2019; 44, 602–610

3. Brockow I., Söhl K., Nennstiel U. Newborn Hearing Screening in Bavaria—Is It Possible to Reach the Quality Parameters?
   Int. J. Neonatal Screen. 2018, 4(3), 26; doi:10.3390/ijns4030026

4. Keller R, Chrastina P, Pavlíková M, et al. Newborn screening for homocystinurias: recent recommendations versus current practice
   J Inherit Metab Dis. 2019 Jan;42(1):128-139. doi: 10.1002/jimd.12034.

5. Gramer G, Fang-Hoffmann J, Feyh P, Klinke G, Monostori P, Okun JG, Hoffmann GF High incidence of maternal vitamin B12 deficiency detected by newborn screening – First results from a study for the evaluation of 26 additional target disorders for the German newborn screening panel
   World Journal of Pediatrics 2018; 14(5), 470-481. doi.org/10.1007/s12519-018-0159-1

6. Chapman KA, Gramer G, Viall S, Summar ML Incidence of maple syrup urine disease, propionic acidemia, and methylmalonic aciduria from newborn screening data
   Mol Genet Metab Rep 2018; 15: 106-109; DOI 10.1016/j.ymgmr.2018.03.011

7. Gramer G, Nennstiel-Ratzel U, Hoffmann GF 50 Jahre Neugeborenenscreening in Deutschland – Bisherige Ergebnisse und zukünftige Herausforderungen
   Monatsschr Kinderheilkd 2018; 166:987–993. doi: 10.1007/s00112-017-0355-4

8. Monostori P*, Klinke G*¶, Richter S, Baráth Á, Fingerhut R, Baumgartner MR, Kölker S, Hoffmann GF, Gramer G*, Okun JG* Simultaneous determination of 3 hydroxypropionic acid, methylmalonic acid and methylcitric acid in dried blood spots: second tier LC MS/MS assay for newborn screening of propionic acidemia, methylmalonic acidemias and combined remethylation disorders
   PLoS One. 2017 Sep 15;12(9):e0184897. doi: 10.1371/journal.pone.0184897. eCollection 2017.*equal contributions

9. Winter T, Lange A, Hannemann A, Nauck M and Müller C. Contamination of dried blood spots – an underestimated risk in newborn screening
   Clin Chem Lab Med 2017

10. Okun JG, Gan-Schreier H, Ben-Omran T, Schmidt KV, Fang-Hoffmann J, Gramer G, Abdoh G, Shahbeck N, Al Rifai H, Al Khal AL, Haege G, Chiang CC, Kasper DC, Wilcken B, Burgard P, Hoffmann GF Newborn Screening for Vitamin B6 Non-Responsive Classical Homocystinuria - Systematical Evaluation of a Two-Tier Strategy
    JIMD Reports 2017; 32: 87-94. doi: 10.1007/8904_2016_556.

11. Gramer G, Abdoh G, Ben-Omran T, Shahbeck N, Ali R, Mahmoud L, Fang-

Hoffmann J, Hoffmann GF, Al Rifai H, Okun JG Newborn screening for remethylation disorders and vitamin B12 deficiency – Evaluation of new strategies in cohorts from Qatar and Germany
World J Pediatr 2017; Apr;13(2):136-143; doi: 10.1007/s12519-017-0003-z.

12. Sommerburg O, Stahl M, Hammermann J, Okun JG, Kulozik A, Hoffmann G, Mall M Newborn Screening on Cystic Fibrosis in Germany: Comparison of the new Screening Protocol with an Alternative Protocol].
Klin Padiatr. 2017 Mar;229(2):59-66. doi: 10.1055/s-0042-124187. Epub 2017 Apr 25. German

13. Gramer G, Hauck F, Lobitz S, Sommerburg O, Speckmann C, Hoffmann GF Neugeborenenscreening 2020 – Perspektiven der Krankheitsfrüherkennung
Monatsschr Kinderheilkd 2017; 165: 216-225; doi: 10.1007/s00112-016-0233-5

14. Staufner C, Haack TB, Feyh P, Gramer G, Raga DE, Terrile C, Sauer S, Okun JG, Fang-Hoffmann J, Mayatepek E, Prokisch H, Hoffmann GF, Kölker S Genetic cause and prevalence of hydroxyprolinemia.
J Inherit Metab Dis. 2016; 39(5): 625-632. doi: 10.1007/s10545-016-9940-2.

15. Kunz JB, Awad S, Happich M, Muckenthaler L, Lindner M, Gramer G, Okun JG, Hoffmann GF, Bruckner T, Muckenthaler MU, Kulozik AE Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening.
Ann Hematol. 2016; 95(3): 397-402. doi: 10.1007/s00277-015-2573-y

16. Weidler S, Stopsack KH, Hammermann J, Sommerburg O, Mall MA, Hoffmann GF, Kohlmüller D, Okun JG, Macek M Jr, Votava F, Krulišová V, Balaščaková M, Skalická V, Lee-Kirsch MA, Stopsack M. A product of immunoreactive trypsinogen and pancreatitis-associated protein as second-tier strategy in cystic fibrosis newborn screening.
J Cyst Fibros. 2016 Nov;15(6):752-758. doi: 10.1016/j.jcf.2016.07.002.

17. Sommerburg O, Hammermann J, Lindner M, Stahl M, Muckenthaler M, Kohlmueller D, Happich M, Kulozik AE, Stopsack M, Gahr M, Hoffmann GF, Mall MA. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany.
Pediatr Pulmonol. 2015 Jul;50(7):655-64. doi: 10.1002/ppul.23190.

18. Gramer G, Haege G, Fang-Hoffmann J, Hoffmann GF, Bartram CR, Hinderhofer K, Burgard P, Lindner M. Medium-Chain Acyl-CoA Dehydrogenase Deficiency: Evaluation of Genotype-Phenotype Correlation in Patients Detected by Newborn Screening
JIMD Rep. 2015; 23:101-12

19. Odenwald B, Nennstiel-Ratzel U, Dörr HG, Schmidt H, Wildner M, Bonfig W. Children with classic congenital adrenal hyperplasia experience salt loss and hypoglycemia: Evaluation of adrenal crises during the first six years of life.
Eur J Endocrinol. 2015; EJE-15-0775. [Epub ahead of print]

20. Odenwald B, Dörr HG, Bonfig W, Schmidt H, Fingerhut R, Wildner M, Nennstiel-Ratzel U. Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase-Deficiency: 13 Years of Neonatal Screening and Follow-up in Bavaria.
Klin Padiatr. 2015; 227(5):278-283

21. Dörr HG, Odenwald B, Nennstiel-Ratzel U. Early Diagnosis of Children with Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficieny by Newborn Screening.
Int. J. Neonatal Scree. 2015; 1(1), 36-44

22. Röschinger W, Sonnenschein S, Schuhmann E, Nennstiel-Ratzel U, Roscher AA, Olgemöller B. Neue Zielerkrankungen im Neugeborenen-Screening:Empfehlungen aus einem Pilotprojekt
Monatsschrift Kinderheilkunde 2015; 2: 142-149

23. Nennstiel-Ratzel U, Lüders A, Blankenstein O. Neugeborenenscreening: ein Paradebeispiel für effektive Sekundärprävention
Bundesgesundheitsblatt 2015; 58: 139-145

24. Janzen N, Terhardt M, Sander S, Demirkol M, Gökcay G, Peter M, Lücke T, Sander J, Das AM. Towards newborn screening for ornithine transcarbamylase deficiency: Fast non chromatographic orotic acid quantification from dried blood spots by tandem mass spectrometry.
Clin. Chim. Acta. 2014; 430, 28-32

25. Nennstiel-Ratzel U, Lüders A, Odenwald B, Mohnike K, Liebl B. Neugeborenenscreening auf angeborene Stoffwechsel- und Hormonstörungen in Deutschland.
gynäkol. prax. 2014; 38: 51-58

26. Baertling F, Mayatepek E, Thimm E, Schlune A, Kovacevic A, Distelmaier F, Salomons GS, Meissner T. Malonic aciduria: long-term follow-up of new patients detected by newborn screening.
Eur J Pediatr. 2014

27. Frömmel C, Brose Am, Klein J, Blankenstein O, Lobitz S. Biomed. Newborn screening for sickle cell disease: technical and legal aspects of a German pilot study with 38,220 participants.
Res Int. 2014; 2014:695828. doi: 10.1155/2014/695828
Epub 2014

28. Brockow I, Praetorius M, Neumann K, Zehnhoff-Dinessen A, Mohnike K, Matulat P, Rohlfs K, Lang-Roth R, Gross M, Duphorn E, Meuret S, Seidel A, Schönfeld R, Schönweiler R, Dienlin S, Rissmann A, Friedrich I, Lehnert B, Nennstiel-Ratzel U. VDHZ: Universal newborn hearing screening : Definition of uniform parameters by the Association of German Hearing Screening Centers as a requirement for nationwide evaluation with valid results.
HNO 2014; 62(3):165-70

29. Hoffmann GF, Lindner M, Loeber JG. 50 years of newborn screening.
J Inherit Metab Dis. 2014; 37(2):163-4. doi: 10.1007/s10545-014-9688-5

30. Lobitz S, Frömmel C, Brose A, Klein J, Blankenstein O.: Incidence of sickle cell disease in an unselected cohort of neonates born in Berlin, Germany.
Eur J Hum Genet. 2014; 22(8):1051-3

31. Blankenstein O. Hydrocortisone replacement in disorders of sex development.
Endocr Dev. 2014; 27:160-71

32. Gramer G, Haege G, Glahn EM, Hoffmann GF, Lindner M, Burgard P Living with an inborn error of metabolism detected by newborn screening – Parents' perspectives on child development and impact on family life
J Inherit Metab Dis 2014; 37:189-195. DOI 10.1007/s10545-013-9639-6.

33. Sommerburg O, Krulisova V, Hammermann J, Lindner M, Stahl M, Muckenthaler M, Kohlmueller D, Happich M, Kulozik AE, Votava F, Balascakova M, Skalicka V, Stopsack M, Gahr M, Macek M Jr, Mall MA, Hoffmann GF. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.
J Cyst Fibros. 2014 Jan;13(1):15-23. doi: 10.1016/j.jcf.2013.06.003.

34. Cloppenborg T, Janzen N, Wagner HJ, Steuerwald U, Peter M, Das AM. Application of a second-tier newborn screening assay for C5 isoforms.
JIMD Reports. 2013; 13, 23-26

35. Janzen N, Steuerwald U, Sander S, Terhardt M, Peter M, Sander J. UPLC-MS/MS analysis of C5-acylcarnitines in dried blood spots.
Clin. Chim. Acta. 2013; 421, 41-45

36. Nennstiel-Ratzel U, Lüders A, Odenwald B, Mohnike K, Liebl B.: Neugeborenenscreening auf angeborene Stoffwechsel- und Hormonstörungen in Deutschland.
tägl.prax. 2013; 54: 771-778

37. Hoehn T, Lukacs Z, Stehn M, Mayatepek E, Philavanh K, Bounnack S.: Establishment of the first newborn screening program in the People's Democratic Republic of Laos.
J Trop Pediatr. 2013; 59(2):95-9

38. Janzen N, Riepe FG, Peter M, Sander S, Steuerwald U, Korsch E, Krull F, Müller HL, Heger S, Brack C, Sander J. Neonatal screening: Identification of children with 11β-hydroxylase deficiency by second-tier testing.
Horm Res. Paediatr. 2012; 77, 195-199

39. Langer A, Brockow I, Nennstiel-Ratzel U, Menn P. The cost-effectiveness of tracking newborns with bilateral hearing impairment in Bavaria: a decision-analytic model.
BMC Health Serv Res. 2012; 12:418

40. Richter-Rodier M, Lange AE, Hinken B, Hofmann M, Stenger RD, Hoffmann W, Fusch C, Haas JP. Ultrasound screening strategies for the diagnosis of congenital anomalies of the kidney and urinary tract.
Ultraschall Med. 2012; 33(7):E333-8

41. Grünert S, Müllerleile S, De Silva L, Barth M, Walter M, Walter K, Meissner T, Lindner M. Et al: 2012. Propionic acidemia: neonatal versus selective metabolic screening.
J Inherit Metab Dis 2012; 35: 41-49

42. Burgard P, Rupp K, Lindner M, Haege G, Rigter T, Weinreich SS, Loeber JG, Taruscio D, Vittozzi L, Cornel MC, Hoffmann GF. Newborn screening programmes in

Europe; arguments and efforts regarding harmonization.Part 2 – From screening laboratory result.
J Inherit Metab Dis 2012; 35: 60-11

43. Steuerwald U, Schroeder C, Holtkamp U, Peter M, Sander J. Fallgruben beim Neugeborenen-Screening.
Pädiatrie Hautnah 2011; 23, 1-4

44. Janzen N, Sander S, Terhardt M, Steuerwald U, Peter M, Das AM, Sander J. Rapid steroid hormone quantification for congenital adrenal hyperplasia (CAH) in dried blood spots using UPLC liquid chromatography-tandem mass spectrometry.
Steroids 2011; 76 1437-1442

45. Brockow I, Kummer P, Liebl B, Nennstiel-Ratzel U. Universelles Neugeborenen-Hörscreening (UNHS) – Ist eine erfolgreiche Umsetzung flächendeckend möglich?
Das Gesundheitswesen 2011; 73: 477-482

46. Nennstiel-Ratzel U, Hoffmann GF, Lindner M. Neugeborenenscreening auf Stoffwechsel- und Hormonstörungen Herausforderungen in Klinik und Praxis
Monatsschr Kinderheilkd 2011; 159:814–820

47. Lüders A, Ceglarek U, Nennstiel-Ratzel U. Register der Deutschen Gesellschaft für Neugeborenenscreening Ergebnisse des Jahres 2008 und Relevanz für Kinderärzte
KJM 2011; 11: 252-254

48. Lindner M, Gramer G, Haege G, Fang-Hoffmann J. Schwab KO, Tacke U. Trefz FK, Mengel E, Wendel U, Leichsenring M, Burgard P, Hoffmann GF.: Efficacy and outcome of expanded newborn screening for metabolic diseases--report of 10 years from South-West Germany.
Orphanet J Rare Dis 2011; 20, 44

49. McHugh DM, Cameron CA, Abdenur JE, Lindner M, et al. Clinical validation of cut-off target ranges in newborn screneing of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project.
Genetics in Medicine 2011; 13: 230-254

50. Janzen N, Sander S, Terhardt M, Das AM, Sass JO, Kraetzner R, Rosevich H, Peter M, Sander J. Rapid quantification of conjugated and unconjugated bile acids and C27 precursors in dried blood spots and small volumes of serum.
J Lipid Res 51 2010; 1591-1598

51. Nennstiel-Ratzel U, Lüders A, Blankenstein O, Ensenauer R, Lindner M, Schulze *A.* Neugeborenenscreening auf metabole und endokrine Störungen: Wie wahrscheinlich ist eine Erkrankung bei auffälligem Befund? *Grundlage für die Aufklärung nach dem Gendiagnostikgesetz*
Monatsschr Kinderheilkd 2010; 158 Suppl.1: S. 36-37

52. Nennstiel-Ratzel U, Lüders A, Blankenstein O, Starke I, Stopsack M, Fingerhut R, Klein J, Lindner M, Müller C, Peter M, Rauterberg E, Stehn M, Schultis W, Fusch C, Schulze A, Ceglarek U. Neugeborenenscreening.
Kinder- und Jugendmedizin 2009; 9, 88-92

53. Nennstiel-Ratzel U, et al. Neugeborenenscreening Qualität des Neugeborenenscreenings in Deutschland nach Inkrafttreten der geänderten Kinderrichtlinie (Screeningrichtlinie) im Jahr 2005
KJM 2009; 9 : 88-92

54. Lukacs Z. Neugeborenenscreening in Deutschland, Österreich und der Schweiz
Monatsschr Kinderheilkd. 2009; 157:1209-1214

55. Zabransky S. Neugeborenescreening auf Endokrinopathien.
Monatsschr Kinderheilkd. 2009; 157:1215-1221

56. Peter M, Janzen N, Sander S, Korsch E, Riepe FG, Sander J. A case of 11β-hydroxylase deficiency detected in a newborn screening program by second-tier LC-MS/MS.
Horm Res 2008; 69, 253-256

57. Sander J, Kattner E, Christoph J, Peter M. Newborn metabolic screening. Requirement to improve preanalytical conditions.
Z Geburtshilfe Neonatol 2008; 212, 1-4

58. Holtkamp U, Klein J, Sander J, Peter M, Janzen N, Steuerwald U, Blankenstein O. EDTA in dried blood spots leads to false results in neonatal endocrinologic screening.
Clin Chem 2008; 54, 602-605

59. Illsinger S, Lücke T, Peter M, Ruiter JPN, Wanders RJA, Deschauer M, Handig I, Wuyts W, Das AM. Carnitine-Palitoyltransferase 2 Deficiency: Novel mutation and relevance of newborn screening.
Am J Med Genet 2008; 146, 2925-2928

60. Nennstiel-Ratzel U, Fusch C, Liebl B. Neugeborenenscreening auf angeborene Stoffwechsel- und Hormonstörungen
Prävention 2008; 117-120

61. Nennstiel-Ratzel U, Brockow I, Wildner M, von Kries R, Strutz J. Hörscreening bei Neugeborenen Modellprojekt in der Oberpfalz und Oberfranken.
päd Praxis 72/Heft4 2008; 587-94

62. Lindner M, Ho S, Kölker S, Abdoh G, Hoffmann GF, Burgard P. Newborn screening for methylmalonic acidurias--optimization by statistical parameter combination.
J Inherit Metab Dis 2008; 31:379-85

63. Janzen N, Peter M, Sander S, Steuerwald U, Terhardt M, Holtkamp U, Sander J. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.
J Clin Endocrinol Metab 2007; 92, 2581-2589

64. Janzen N, Sander S, Terhardt M, Peter M, Sander J.Fast and direct quantification of adrenal steroids by tandem mass spectrometry in serum and dried blood spots.
J Chromatogr B Analyt Technol Biomed Life Sci 2007; 861,117-122

65. Lindner M, Abdoh G, Fang-Hoffmann J, Shabeck N, Al-Sayrafi M, Al-Janahi M, Ho S, Abdelrahman MO, Ben-Omran T, Bener A, Schulze A, Al-Rifai H, Al-Thani G, Hoffmann GF. Implementation of extended neonatal screening and a metabolic unit in the State of Qatar: Developing and optimizing strategies in cooperation with the Neonatal Screening Center in Heidelberg.
J Inherit Metab Dis 2007; 30: 522-9

66. Bodamer OA, Hoffmann GF, Lindner M. Expanded newborn screening in Europe 2007.
J Inherit Metab Dis 2007; 30: 439-44

67. Ho S, Lukacs Z, Hoffmann GF, Lindner M, Wetter T. Feature construction can improve diagnostic criteria for high-dimensional metabolic data in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency.
Clin-Chem 2007; 53: 1330-7

68. Sander J, Janzen N, Peter M, Sander S, Steuerwald U, Holtkamp U, Schwahn B, Mayatepek E, Trefz FK, Das AM. Newborn screening for hepatorenal tyrosinemia: Tandem mass spectrometric Quantification of succinylacetone.
Clin Chem 2007; 52, 482-487

69. Lindner M, Ho S, Fang-Hoffmann J, Hoffmann GF, Kölker S. Neonatal screening for glutaric aciduria type I: Strategies to proceed.
J Inherit Metab Dis 2006; 29:378-382

70. Sander J, Janzen N, Peter M, Sander S, Steuerwald U, Holtkamp U, Schwahn B, Mayatepek E, Trefz FK, Das, AM. Newborn screening for hepatorenal tyrosinemia: Tandem mass spectrometric Quantification of succinylacetone.
Clin Chem. 52, 482-487 (2006)

71. Sander J, Sander S, Steuerwald U, Janzen N, Peter M, Wanders RJA, Marquardt I, Korenke J, Das AM. Neonatal screening for defects of the mitochondrial trifunctional protein.
Mol Genet Metab 2005; 85, 108-114

72. Nennstiel-Ratzel U, Arenz S, Maier EM, Knerr I, Baumkötter J, Röschinger W, Liebl B, Hadorn HB, Roscher AA, von Kries R. Reduced incidence of severe metabolic crisis or death in children with medium chain acyl-CoA dehydrogenase deWciency homozygous for c.985A>G identiWed by neonatal screening.
Molecular Genetics and Metabolism 2005; 85: 157-159

73. Stöckler-Ipsiroglu S, Herle M, Nennstiel-Ratzel U, Wendel U, Burgard P, Plecko B, Ipsiroglu O. Besonderheiten in der Betreuung von Kindern mit angeborenen Stoffwechselerkrankungen aus Migrantenfamilien
Monatsschr Kinderheilkd 2005; 153:22-28

74. Maier EM, Liebl B, Röschinger W, Nennstiel-Ratzel U, Fingerhut R, Olgemöller B, Busch U, Krone N, von Kries R, Roscher AA. Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for mediumchain acyl-CoA dehydrogenase deficiency.
Hum. Mutat 2005; 25:443-452

75. Lindner M, Hoffmann GF. Neugeborenenscreening und rationale Diagnostik bei klinischen Problemstellungen.
Klinikarzt 2005; 34: 50-54

76. Lindner M, Kölker S, Schulze A, Christensen E, Greenberg CR, Hoffmann GF. J Inherit Neonatal screening for glutaryl-CoA dehydrogenase deficiency.
Inherit Metab Di 2004; 27: 851-9

77. Hoffmann GF, von Kries R, Klose D, Lindner M, Schulze A, Muntau AC, Röschinger W, Liebl B, Mayatepek E, Roscher AA. Frequencies of inherited organic acidurias and disorders of mitochondrial fatty acid transport and oxidation in Germany.
Eur J Pediatr 2004; 163: 76-80

78. Liebl B, Nennstiel-Ratzel U, Roscher A, von Kries R. Data required for the evaluation of newborn screening programmes.
Eur J Pediatr 2003; 162 Suppl 1:S57-61

79. Nennstiel-Ratzel U, Liebl B, Zapf A. Modellprojekt zur Neuordnung des Neugeborenen-Screening in Bayern.
Das Gesundheitswesen 2003; 65 Suppl 1:S31-5

80. Schulze A, Lindner M, Kohlmüller D, Olgemöller K, Mayatepek E, Hoffmann GF. Expanded Newborn Screening for Inborn Errors of Metabolism by Electrospray Ionization-Tandem Mass Spectrometry: Results, Outcome, and Implications.
Pediatrics 2003; 111: 1399 – 1406

81. Liebl B, Nennstiel-Ratzel U, von Kries R, Fingerhut R, Olgemöller B, Zapf A, Roscher AA. Expanded newborn screening in Bavaria: tracking to achieve requested repeat testing.
Prev Med 2002; 34(2):132-7

82. Liebl B, Nennstiel-Ratzel U, von Kries R, Fingerhut R, Olgemöller B, Zapf A, Roscher AA. Very high compliance in an expanded MS-MS-based newborn screening program despite written parental consent.
Prev Med 2002; 34(2):127-31

83. Okun JG, Kölker S, Schulze A, Kohlmüller D, Olgemöller K, Lindner M, Hoffmann G, Wanders R, Mayatepek E. A method for quantitative acylcarnitine profiling in human skin fibroblasts using unlabelled palmitic acid: diagnosis of fatty acid oxidation disorders and differentiation between biochemical phenotypes of MCAD deficiency.
Biochim-Biophys Acta 2002; 10, 1584: 91-8

84. Liebl B, von Kries R, Nennstiel-Ratzel U, Muntau AC, Röschinger W, Olgemöller B, Zapf A, Roscher AA. Überlegungen zu ethisch-rechtlichen Aspekten des Neugeborenen-Screenings.
Neugeborenenscreening Monatsschr Kinderheilkd 2001; 149:1326–1335

85. Zschocke J, Schulze A, Lindner M, Fiesel S, Olgemöller K, Hoffmann GF, Penzien J, Ruiter JP, Wanders RJ, Mayatepek E. Molecular and functional characterisation of mild MCAD deficiency.
Hum Genet. 2001; 108: 404-8

86. Lindner M, Schulze A, Zabransky S, Engelhorn K, Hoffmann G. Früherkennung von Stoffwechselerkrankungen - Neue Entwicklungen im Neugeborenenscreening. Medizinische Genetik 4 2001; 342-347